Medical News

RSS

Energizer Holdings reports 6% increase in second-quarter 2010 net sales

Energizer Holdings, Inc., today announced results of its second quarter ended March 31, 2010. Net earnings for the quarter were $88.5 million, or $1.25 per diluted share, versus net earnings of $77.0 million, or $1.30 per diluted share in the second fiscal quarter of 2009.

27 Apr 2010

Nuvo Research's PENNSAID now available in U.S. pharmacies

Nuvo Research Inc., a drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that PENNSAID(R) (diclofenac sodium topical solution) 1.5% w/w, is now available by prescription in U.S. pharmacies.

27 Apr 2010

IntegraMed America's Vein Clinics business grows 20% in first-quarter 2010

IntegraMed America, Inc., the leader in developing and managing specialty healthcare facilities in the fertility and vein care markets, today announced strong results for the first quarter ended March 31, 2010.

27 Apr 2010

Study: Cigarette smoking, fructose consumption can worsen NAFLD

Recent studies suggest that modifiable risk factors such as cigarette smoking and fructose consumption can worsen nonalcoholic fatty liver disease. With NAFLD, fat accumulates in the liver of overweight individuals despite drinking little alcohol, causing in some cases liver scarring that can lead to liver failure.

27 Apr 2010

Amedisys' first-quarter 2010 net service revenues up 20.8%

Amedisys, Inc., one of America's leading home health nursing companies, today reported its financial results for the three-month period ended March 31, 2010. We posted record financial performance with net service revenue and net income attributable to Amedisys, Inc., increasing 20.8% and 35.6%, respectively, over the three-month period ended March 31, 2009.

27 Apr 2010

Compugen reports revenues of $125,000 for first-quarter 2010

Compugen Ltd. today reported financial results for the first quarter ending March 31, 2010.

27 Apr 2010

First Edition: April 27, 2010

Today's headlines focus on the details of health reform that continue to emerge -- including states' reactions to high risk pools and questions about the sweeping expansion of Medicaid.

27 Apr 2010

Pharmacological suppression of nonsense mutations effective in treating genetic defects

Genetic mutation can disrupt the way human cells make proteins, which in turn leads to inherited disease. David Bedwell, a professor in the University of Alabama at Birmingham (UAB) Department of Microbiology, says scientists are closer than ever to producing drugs that fix this disrupted-protein pathway and drastically improving treatment of genetic disease.

27 Apr 2010

MMC announces acquisition of BGR.com

Mail.com Media Corporation, the digital media company that owns and operates the Mail.com portal and email service as well as a growing portfolio of lifestyle brands including, Deadline.com, HollywoodLife.com, Movieline.com and OnCars.com, announced today its acquisition of BGR.com, one of the top mobile/gadget sites in the world.

27 Apr 2010

Universite de Montreal demographer offers prediction of boomer future

Baby boomers are retiring healthy, financially secure and with a desire to travel. According to Universit- de Montr-al demographer Jacques L-gar-, baby boomers will remain among the most self-reliant generations to reach their golden years.

27 Apr 2010

High levels of phosphate in sodas accelerate signs of aging

Here's another reason to kick the soda habit. New research published online in the FASEB Journal shows that high levels of phosphates may add more "pop" to sodas and processed foods than once thought. That's because researchers found that the high levels of phosphates accelerate signs of aging. High phosphate levels may also increase the prevalence and severity of age-related complications, such as chronic kidney disease and cardiovascular calcification, and can also induce severe muscle and skin atrophy.

27 Apr 2010

Medication-free home ventilation system designed to remove allergens

According to a recent report by USA Today, due to 2010's unusually cold winter temperatures, allergy sufferers are now poised to experience the worst pollen season in years, with pollen counts skyrocketing and sufferers hiding indoors to avoid exposure. Yet as allergens creep indoors, sufferers continue to cough, sneeze and seek relief. With the introduction of EZ Breathe, a new innovative home ventilation system designed to remove allergens and reduce indoor concentrations of pollen, allergy sufferers now have a medication-free solution.

27 Apr 2010

DNASTAR, Scarab Genomics announce launch of DNA and RNA sequencing services business

DNASTAR and Scarab Genomics, sister companies founded by genomics pioneer Fred Blattner, announce the launch of a next-generation DNA and RNA sequencing services business. Using their combined expertise, the companies will be offering a full range of sequencing services including library preparation, coordinating the most appropriate sequencing technology and platform, assembly, analysis, annotation, and visualization of end results.

27 Apr 2010

ICON reports net revenues of $219 million for first-quarter 2010

ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2010.

27 Apr 2010

Prime-boost malaria vaccine regimen provides sterile protection: Vical

Vical Incorporated announced today that a prime-boost malaria vaccine regimen provided sterile protection, with no disease symptoms and no detectable malaria parasites, in 4 of 15 vaccinated volunteers a full 28 days after challenge with multiple infected-mosquito bites.

27 Apr 2010

Researchers to commence enrolling participants in National Children's Study

After years of planning, UT Southwestern Medical Center researchers are ready to begin enrolling participants in the National Children's Study, which will examine the effects of environmental and genetic factors on child and adult health.

27 Apr 2010

Protalix BioTherapeutics submits validation data for taliglucerase alfa manufacturing process to the FDA

Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.

27 Apr 2010

MicroStockProfit.com announces investment report featuring BioElectronics

MicroStockProfit.com announces an investment report featuring BioElectronics Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

27 Apr 2010

UK MHRA authorizes Presidio Pharmaceuticals to initiate Phase 1 clinical trial of PPI-461 for HCV

Presidio Pharmaceuticals, Inc. announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the initiation of a Phase 1 first-in-human clinical trial of PPI-461, an orally administered NS5A inhibitor for the treatment of hepatitis C virus (HCV). The Phase 1 clinical trial will be conducted in healthy volunteers.

27 Apr 2010

Ashland reports 13% increase in sales from $1,990M to $2,248M for second-quarter 2010

For its 2010 second quarter, Ashland reported sales of $2,248 million, operating income of $151 million and net income of $22 million (27 cents per share). Net income was favorably affected by $2 million aftertax (2 cents per share) from discontinued operations. Cash flows provided by operating activities from continuing operations amounted to $183 million.

27 Apr 2010